AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Amgen Inc
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S5NNL6
414.87▲ 7.43 (1.82%)
As of 2026-10-09
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
407.44
Day's Range
404.05 – 417.78
52-Week Range
288.00 – 447.03
Volume
2.0M
Avg Volume
2.8M
Share Statistics
Shares Outstanding
Employees
31.5K
Exchange
XNAS
Listed
1983-06-17
Share count as of July 30, 2026

Amgen Inc (AMGN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Amgen Inc (AMGN)
What is Amgen Inc's Market Cap?
Amgen Inc's Market Cap is $224.3B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Enterprise Value?
Amgen Inc's Enterprise Value is $267.6B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Trailing P/E?
Amgen Inc's Trailing P/E is 25.7×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Price / Sales?
Amgen Inc's Price / Sales is 5.9×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's EV / Revenue?
Amgen Inc's EV / Revenue is 7.0×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's EV / EBITDA?
Amgen Inc's EV / EBITDA is 16.6×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Revenue (TTM)?
Amgen Inc's Revenue (TTM) is $38.1B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Net Income (TTM)?
Amgen Inc's Net Income (TTM) is $8.7B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's EBITDA?
Amgen Inc's EBITDA is $16.1B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Diluted EPS (TTM)?
Amgen Inc's Diluted EPS (TTM) is 16.17, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AMGNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth+9.5%+5.8%+8.6%+12.4%
Operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Other
Total operating expenses
% of revenue65.0%69.1%72.4%73.6%
Operating income
% of revenue35.0%30.9%27.6%26.4%
Other income (expense):
Interest expense, net
Other (expense) income, net
Income before income taxes
Provision for income taxes
Net income
% of revenue23.6%21.1%13.5%33.7%
Basic (in usd per share)
Diluted (in usd per share)